Determination of Etoricoxib in Bulk and Pharmaceutical Dosage Forms by UV Spectrophotometric Method

Manish Kumar Thimmaraju*1, Venkat Rao2, Hemanth.K3, Siddartha.K4

1,2,4Central Analytical Laboratory, Balaji Institute of Pharmaceutical Sciences
Warangal, AP, India

3Shantha Institute of Pharmaceutical Sciences, Huzurabad, AP, India

*Corres.author: manishcancer@gmail.com

Abstract: A Simple, rapid, accurate and economical UV Spectrophotometric method is developed for determination of etoricoxib in bulk and tablets. In chloroform, the $\lambda_{\text{max}}$ of the drug was found to be 247 nm. Using double-beam Analytical Technologies Limited, model T60 UV-Visible spectrophotometer connected to computer loaded with UV Win 5.0 software, in this proposed method etoricoxib follows linearity in the concentration range 1 – 40 µg/ml with a correlation coefficient of 0.998. Assay results were in good agreement with label claim. The methods were validated statistically and by recovery studies. The relative standard deviation was found to be 0.2319 with excellent precision and accuracy. The proposed method is specific while estimating the commercial formulations without interference of excipients and other additives. Hence, this method can be used for the routing determination of Etoricoxib in bulk samples and pharmaceutical formulations.

Key words: Etoricoxib, UV spectroscopy, Chloroform.

1. INTRODUCTION

Etoricoxib is a non steroidal anti inflammatory drug and highly COX-2 inhibitor1-12. Etoricoxib, 5-chloro-6’-methyl-3-[4-(methylsulfonyl)phenyl]-2,3’-bipyridine, produces dose dependent inhibition of COX-2 without inhibition of COX-1. It does not inhibit gastric prostaglandin synthesis and has no effect on platelet function. COX-2 inhibition provides anti-inflammatory and analgesic effects13-14. It is used for symptomatic management of osteoarthritis15-19, rheumatoid arthritis20-24, primary dysmenorrhoea, postoperative dental pain, acute gouty arthritis25, cancer treatment and prevention and migraine26-31. According to the literature survey it was found that few analytical methods such as Visible, UV, HPLC other methods were reported for etoricoxib(S.R. Shahi, et al 2008, M.J. Rose, et al 2002, Robert Hartaman, et al32-34.) The objective of the proposed methods to develop simple and accurate method for the determination of etoricoxib by UV spectrophotometric method in Pharmaceutical dosages forms.

Fig-1 Etoricoxib
2. METHODS AND MATERIALS

Instruments
A double-beam Analytical Technologies Limited, model T60 UV-Visible spectrophotometer connected to computer loaded with UV Win 5.0 software. The instrument has an automatic Wavelength accuracy of 1 nm and matched quartz cells of 10 mm path length.

Chemicals and Reagents
Etoricoxib, Chloroform (A.R.GRADE), Tablet formulation (RETOZ-60)

Preparation of standard stock solution and study of calibration curves
The standard stock solution was prepared by dissolving etoricoxib in chloroform to make final concentration of 100 $\mu$g/ml. Different aliquots were taken from stock solution and diluted with chloroform separately to prepare series of concentrations from 1-40 $\mu$g/ml. The $\lambda_{\text{max}}$ was found by UV spectrum of etoricoxib in chloroform, in the range of 200-400 nm and it was found to be 247 nm. Absorbance was measured at 247 nm against chloroform as blank. The calibration curve was prepared by plotting absorbance versus concentration of Etoricoxib. The calibration curve was shown in fig-2, UV spectra fig-3.

Preparation of sample solution
20 tablets of marketed formulation containing Etoricoxib were taken and powdered. The powder equivalent to 10mg of Etoricoxib was dissolved in 50 ml of chloroform, sonicated for 10 mins and filtered, and total volume is adjusted to 100ml with chloroform. Different aliquots were taken from sample stock solution and diluted with chloroform separately to prepare series of concentrations from 1-40 $\mu$g/ml. The $\lambda_{\text{max}}$ was found by UV spectrum of etoricoxib in chloroform, in the range of 200-400 nm and it was found to be 247 nm. Absorbance was measured at 247 nm against chloroform as blank. The prepared solutions were measured at 247nm against chloroform as blank. Then the amount of drug present in the formulations was calculated. The results were shown in Table-1.

Figure -1
Figure-2

![Absorbance graph with wavelength (nm) on the x-axis and absorbance on the y-axis.](image)

### Table 1: Results of assay

<table>
<thead>
<tr>
<th>Drug</th>
<th>Sample No</th>
<th>Amount Labeled (mg/tab)</th>
<th>Amount Estimated (mg/tab)</th>
<th>% of label Claim</th>
<th>% Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etoricoxib</td>
<td>1</td>
<td>60</td>
<td>59.64</td>
<td>99.4</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>60</td>
<td>59.66</td>
<td>99.43</td>
<td>0.57</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>60</td>
<td>59.66</td>
<td>99.43</td>
<td>0.57</td>
</tr>
</tbody>
</table>

### Table 2: Summary of UV Method

<table>
<thead>
<tr>
<th>UV METHOD</th>
<th>Etoricoxib</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption Maximum</td>
<td>247</td>
</tr>
<tr>
<td>Linearity Range (µg/ml)</td>
<td>1 - 40</td>
</tr>
<tr>
<td>Slope</td>
<td>0.0613</td>
</tr>
<tr>
<td>Correlation Coefficient (r)</td>
<td>0.999</td>
</tr>
<tr>
<td>% RSD of slope</td>
<td>6.76</td>
</tr>
<tr>
<td>Label claim (mg/tablet)</td>
<td>60</td>
</tr>
<tr>
<td>Amount found</td>
<td>59.65</td>
</tr>
<tr>
<td>S.D</td>
<td>0.0115</td>
</tr>
<tr>
<td>RSD%</td>
<td>0.01935</td>
</tr>
<tr>
<td>% Recovery</td>
<td>99.01</td>
</tr>
</tbody>
</table>
3. METHOD VALIDATION

Precision
The precision of the proposed method was ascertained by actual determination of eight replicates of fixed amount of the drug. Results given below in Table-3.

Recovery studies
The recovery studies were carried out at three different levels i.e. 80%, 100% and 120% level. To ensure the reliability of the above method, recovery studies were carried out by mixing a known quantity of standard drug with the preanalysed sample formulation and the contents were reanalyzed by the proposed method. The percentage recovery was found and shown in Table-4.

Table -3:Precision (Etoricoxib)

<table>
<thead>
<tr>
<th>S.N.</th>
<th>Concentration (µg/ml)</th>
<th>Absorbance</th>
<th>Average</th>
<th>S D</th>
<th>%RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20</td>
<td>1.228</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>1.230</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>20</td>
<td>1.229</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>1.228</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>20</td>
<td>1.229</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>20</td>
<td>1.228</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>20</td>
<td>1.228</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>20</td>
<td>1.228</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The proposed method shows the precision with SD 0.00075 and %RSD 0.0615

Table -4

<table>
<thead>
<tr>
<th>Drug</th>
<th>Amount Added (µg/ml)</th>
<th>Amount recovered (µg/ml)</th>
<th>Percentage recovery (%)</th>
<th>Average Recovery</th>
<th>%RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etoricoxib</td>
<td>16</td>
<td>15.97</td>
<td>99.81</td>
<td>99.01</td>
<td>1.2276</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>19.92</td>
<td>99.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>23.96</td>
<td>99.8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. RESULTS AND DISCUSSION

From the optical characteristics of the proposed method it was found that the drug obeys linearity within the concentration range of 1-40 µg/ml. From the results it was found that the percent RSD is less than 2% which indicates that the method has good reproducibility, the percent recovery values of pure drug from the preanalysed solutions of formulations were in between 99.81 -99.8%, which indicates that the method is accurate and which reveals the commonly used excipients and additives present in the pharmaceutical formulations did not interfere in the proposed method.

The proposed method was simple, sensitive and reliable with good precision and accuracy. The proposed method is specific while estimating the commercial formulations without interference of excipients and other additives. Hence, this method can be used for the routing determination of Etoricoxib in bulk samples and pharmaceutical formulations.

5. ACKNOWLEDGEMENT

I am very much thankful to Professor and Principal Dr. N. Raghunandan, Balaji Institute of Pharmaceutical Sciences, Warangal, for his guidance, kind help and constant encouragement at every step during the progress of my work. I am also grateful to my scholars and my friends for their kind help from time to time at each and every step of this work.
6. REFERENCES

3. ClIMS 85 April 2004 pg 32 continued on pg 55.
4. Cims a move ahead in pain management pg24
8. Prescription list. Com
10. Uma Maheswari R., Sathish Kumar D., Parthiban


*****